Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HBB | P68871 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4288878 | 0.78 | ATM (0.44) | ATMNPC1RAB9A | |
| SCHEMBL6081734 | 0.78 | ATM (0.44) | ATMNPC1RAB9A | |
| SCHEMBL8626591 | 0.74 | ATM (0.40) | ATMNPC1RAB9AKDM4E | |
| SCHEMBL5712412 | 0.74 | MEN1 (0.42) | ATMNPC1RAB9AALDH1A1 | |
| SCHEMBL4700076 | 0.73 | CA12 (0.37) | ATMKDM4EALDH1A1HBBHSD17B10 | |
| SCHEMBL12478396 | 0.73 | ATM (0.39) | ATMNPC1RAB9AKDM4E | |
| SCHEMBL9769252 | 0.69 | ATM (0.45) | ATMNPC1RAB9AKDM4E | |
| SCHEMBL4620642 | 0.68 | ATM (0.48) | ATMNPC1RAB9AKDM4E | |
| SCHEMBL8424490 | 0.68 | ATM (0.48) | ATMNPC1RAB9AKDM4E | |
| SCHEMBL5259264 | 0.68 | ATM (0.48) | ATMNPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014179528-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS | BROWN DENNIS M (US) | 2014-11-06 | — | — | WO | claimed |
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | EDISON ONCOLOGY (US) | 2024-05-16 | — | — | US | disclosed |
| EP-4297746-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED COMPOUNDS AND THERAPIES FOR THE TREATMENT OF DISEASES | Edison Oncology (US) | 2024-01-03 | — | — | EP | disclosed |
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2023-05-04 | — | — | US | disclosed |
| WO-2023069727-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | EDISON ONCOLOGY (US) | 2023-04-27 | — | — | WO | disclosed |
| CN-115813902-A | Use of substituted hexitols for the treatment of malignant tumors | 德玛公司 | 2023-03-21 | — | — | CN | disclosed |
| US-20230017948-A1 | COMBINATION THERAPY USING FABP5 INHIBITORS WITH TAXANES FOR TREATMENT OF CANCER | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2023-01-19 | — | — | US | disclosed |
| US-11541027-B2 | Use of dianhydrogalactitol and analogs or derivatives thereof in combination with platinum-containing antineoplastic agents to treat non-small-cell carcinoma of the lung and brain metastases | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2023-01-03 | — | — | US | disclosed |
| US-20220193024-A1 | USE OF SUBSTITUTED HEXITOLS INCLUDING DIANHYDROGALACTITOL AND ANALOGS TO TREAT NEOPLASTIC DISEASE AND CANCER STEM CELLS INCLUDING GLIOBLASTOMA MULTIFORME AND MEDULLOBLASTOMA | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2022-06-23 | — | — | US | disclosed |
| US-20220142966-A1 | USE OF SUBSTITUTED HEXITOLS INCLUDING DIANHYDROGALACTITOL AND ANALOGS TO TREAT NEOPLASTIC DISEASE AND CANCER STEM CELLS INCLUDING GLIOBLASTOMA MULTIFORME AND MEDULLOBLASTOMA | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2022-05-12 | — | — | US | disclosed |
| CN-1976906-B | Substituted 2-alkyl quinazolinone derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA NV | 2010-09-01 | — | — | CN | disclosed |
| CN-1976906-B | Substituted 2-alkyl quinazolinone derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA NV | 2010-09-01 | — | — | CN | disclosed |
| EP-2215075-A1 | QUINOLINONE DERIVATIVES AS PARP INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2010-08-11 | — | — | EP | disclosed |
| US-20100168065-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-01 | — | — | US | disclosed |
| EP-2134691-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2009-12-23 | — | — | EP | disclosed |
| WO-2009118382-A1 | TETRAHYDROPHENANTHRIDINONES AND TETRAHYDROCYCLOPENTAQUINOLINONES AS PARP AND TUBULIN POLYMERIZATION INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009053373-A1 | QUINOLINONE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-30 | — | — | WO | disclosed |
| WO-2008107478-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-09-12 | — | — | WO | disclosed |
| CN-1976906-A | Substituted 2-alkyl quinazolinone derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2007-06-06 | — | — | CN | disclosed |
| CN-1976906-A | Substituted 2-alkyl quinazolinone derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2007-06-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | ATM 2664/4885NPC1 2833/4885RAB9A 3182/4885 |
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | TOP2A, TOP2B, TOP1 | ATM 1132/4885NPC1 1072/4885RAB9A 2294/4885 |
| US-20220142966-A1 | USE OF SUBSTITUTED HEXITOLS INCLUDING DIANHYDROGALACTITOL AND ANALOGS TO TREAT NEOPLASTIC DISEASE AND CANCER STEM CELLS INCLUDING GLIOBLASTOMA MULTIFORME AND MEDULLOBLASTOMA | MGMT, MPG, HDAC7 | ATM 1063/4885NPC1 4146/4885RAB9A 4459/4885 |
| US-20220193024-A1 | USE OF SUBSTITUTED HEXITOLS INCLUDING DIANHYDROGALACTITOL AND ANALOGS TO TREAT NEOPLASTIC DISEASE AND CANCER STEM CELLS INCLUDING GLIOBLASTOMA MULTIFORME AND MEDULLOBLASTOMA | MGMT, MPG, HDAC7 | ATM 1063/4885NPC1 4146/4885RAB9A 4459/4885 |
| US-20230017948-A1 | COMBINATION THERAPY USING FABP5 INHIBITORS WITH TAXANES FOR TREATMENT OF CANCER | FABP5, FABP4, FABP1 | ATM 3519/4885NPC1 342/4885RAB9A 4397/4885 |
| US-20100168065-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | PARP1, PARP11, PARP3 | ATM 110/4885NPC1 3701/4885RAB9A 2880/4885 |
| US-11541027-B2 | Use of dianhydrogalactitol and analogs or derivatives thereof in combination with platinum-containing antineoplastic agents to treat non-small-cell carcinoma of the lung and brain metastases | DNMT1, MGMT, DCK | ATM 29/4885NPC1 4776/4885RAB9A 4696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.